Comparison between direct factor Xa inhibitors and low-molecular-weight heparin for efficacy and safety in the treatment of cancer-associated venous thromboembolism: A meta-analysis

Simple item page
dc.contributor.authorYang, Minen_US
dc.contributor.authorLi, Jiangen_US
dc.contributor.authorRui, Sunen_US
dc.contributor.authorWang, Yanfengen_US
dc.contributor.authorHaiyan, Xuen_US
dc.contributor.authorBoyan, Yangen_US
dc.contributor.authorXiaoming, Wuen_US
dc.contributor.authorLei, Yuen_US
dc.date.accessioned2020-11-18T10:07:33Z
dc.date.available2020-11-18T10:07:33Z
dc.date.issued2020-01
dc.description.abstractAim of the Study: The role of direct-acting oral anticoagulants in the treatment of venous thromboembolism (VTE) in cancer patients compared with the current standard of low-molecular-weight heparin (LMWH) treatment remains unclear. This meta-analysis aimed to evaluate the efficacy and safety of direct factor Xa inhibitors compared with those of LMWH in the treatment of cancer-associated VTE. Materials and Methods: We systematically searched PubMed, EMBASE, Cochrane library, and Web of Science for potential randomized controlled clinical trials and retrospective cohort studies. Data on recurrent VTE (efficacy) and major and minor bleeding events (safety) were extracted, and the odds risks (OR) were analyzed using a random-effect model. Results: A total of nine studies involving 4208 cancer patients with VTE were included in these analyses. Pooled analysis showed that direct factor Xa inhibitors were significantly superior to LMWH in reducing the risk of recurrent VTE (OR = 0.67; 95% confidence interval [CI]: 0.54–0.82). There was no significant difference in the rate of major bleeding between the direct factor Xa inhibitor and LMWH treatments (OR = 1.25; 95% CI: 0.94–1.65). However, the rate of minor bleeding events was higher when a direct factor Xa inhibitor was used instead of LMWH (OR = 1.80; 95% CI: 1.05–3.07). Conclusions: Direct factor Xa inhibitors are superior to LMWH in efficacy in the treatment of VTE in cancer patients, and the safety between the two regimens is comparable except for a slightly higher rate of minor bleeding when the former is useden_US
dc.identifier.affiliationsDepartment of Comprehensive Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Chinaen_US
dc.identifier.affiliationsOffice of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Chinaen_US
dc.identifier.affiliationsDepartment of Comprehensive Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Chinaen_US
dc.identifier.affiliationsDepartment of Comprehensive Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Chinaen_US
dc.identifier.affiliationsDepartment of Comprehensive Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Chinaen_US
dc.identifier.affiliationsDepartment of Comprehensive Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Chinaen_US
dc.identifier.affiliationsDepartment of Comprehensive Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Chinaen_US
dc.identifier.citationYang Min, Li Jiang, Rui Sun, Wang Yanfeng, Haiyan Xu, Boyan Yang, Xiaoming Wu, Lei Yu. Comparison between direct factor Xa inhibitors and low-molecular-weight heparin for efficacy and safety in the treatment of cancer-associated venous thromboembolism: A meta-analysis. Journal of Cancer Research and Therapeutics. 2020 Jan; 15(6): 1541-1546en_US
dc.identifier.issn0973-1482
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/213568
dc.languageenen_US
dc.publisherWolters Kluwer India Pvt. Ltd.en_US
dc.relation.issuenumber6en_US
dc.relation.volume15en_US
dc.source.urihttps://dx.doi.org//10.4103/jcrt.JCRT_68_19en_US
dc.subjectCancer-related venous thromboembolismen_US
dc.subjectdirect-acting oral anticoagulantsen_US
dc.subjectefficacyen_US
dc.subjectlow-molecular-weight heparinen_US
dc.subjectsafetyen_US
dc.titleComparison between direct factor Xa inhibitors and low-molecular-weight heparin for efficacy and safety in the treatment of cancer-associated venous thromboembolism: A meta-analysisen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Ijcrt2019v15n7p1541.pdf
Size:
1.42 MB
Format:
Adobe Portable Document Format
Download
Collections
Journal of Cancer Research and Therapeutics